No is my vote on the equity incentive plan unless there is significant news between now and the time of the meeting. The science of leronlimab has brought the drug close to the forefront of COVID, but NP has fumbled many times along the way (I won’t make a list because we’ve covered this many times) and those fumbles have been costly.

If leronlimab gets approved for COVID in the U.K. or in the US, then by all means, Increase the incentive plan and compensate NP and other board members for their efforts. But not until that point because CYDY does still not have a revenue stream and will require further dilution (aka terrible Fife deals) until that point. They should create a compensation plan like the one for cancer BTD which is based on merit.